Fentanyl intranasal spray - Kyowa Kirin International

Drug Profile

Fentanyl intranasal spray - Kyowa Kirin International

Alternative Names: Fentanyl; Fentanyl pectin; Fentanyl pectin nasal spray; FPNS; Lazanda; Nasalfent; PecFent

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator West Pharmaceutical Services
  • Developer AstraZeneca; Kyowa Kirin International; ProStrakan
  • Class General anaesthetics; Opioid analgesics; Piperidines; Small molecules
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Cancer pain
  • Phase I Anaesthesia

Most Recent Events

  • 01 Mar 2018 Fentanyl intranasal spray is licensed to Slan Medicinal Holdings in Canada and USA
  • 07 Nov 2017 Depomed enters into agreement to divest fentanyl intranasal spray to Slan Medicinal Holdings
  • 26 May 2017 Phase-I development in Anaesthesia (Adjuvant therapy) is ongoing in USA (Intranasal, Spray)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top